[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hscrp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hscrp":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100449382","rir-and-the-impact-on-clinical-outcomes-in-patients-undergoing-pci-100449382",false,"NCT05131750","RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI","A Prospective Study of Residual Inflammatory Risk and the Impact on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Interventions","Inclusion Criteria:\n\n1. Participants who understand and sign the informed consent form voluntarily;\n2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex;\n3. The hospitalized patients with coronary heart disease undergoing PCI;\n4. Complete all planned PCI during hospitalization\n\nExclusion Criteria:\n\n1. Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease;\n2. Uncontrolled infectious diseases during the screening period;\n3. In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on;\n4. Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period;\n5. Surgical or interventional treatment was performed within 3 months before the screening period;\n6. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives;\n7. Participated in other clinical trials within 3 months before the screening period;\n8. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},1408,"ESTIMATED","OBSERVATIONAL","Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular events (MACE).\n\nAt present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Foreign studies indicate that hsCRP ≥ 2mg \u002F L is the definition standard of RIR in CAD. In China, there is no defined value of RIR for patients undergoing PCI, and the incidence of RIR has not been investigated clearly. At the same time, the impact of dynamic changes of hsCRP on MACE in PCI population needs to be further explored. Therefore, in this study, we plan to recruit patients undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the prognosis of these patients followed up for 5 years.",[25],"hsCRP","RECRUITING","2026-08-31",{"date":29,"type":30},"2026-09-02","ACTUAL",{"date":32,"type":30},"2021-05-06",{"date":34,"type":21},"2028-12-31",{"name":36,"class":37},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":38},"100592771","association-between-gradebcof-stage-iii-and-iv-periodontitis-and-high-sensitivity-c-reactive-protein-level-in-serum-and-oral-rinse-sample-100592771","NCT06997770","Association Between Grade(B\u002FC)of Stage III and IV Periodontitis and High Sensitivity C Reactive Protein Level in Serum and Oral Rinse Sample","Association Between Grade (B\u002FC)of Stage III and Stage IV Periodontitis and High Sensitivity C Reactive Protein Levels in Serum and Oral Rinse Sample :A Cross Sectional Study","Inclusion Criteria:\n\n* Patients in the age group of (18-50 years)\n* Presence of ≥ 20 natural teeth\n* Ability and willingness to give written informed consent\n* Patients belonging to 3 groups -periodontally healthy, stage III and stage IV grade B periodontitis, and stage III and stage IV grade C periodontitis .\n\nExclusion Criteria:\n\n* • Patients with chronic inflammatory disease such as nephrotic syndrome, chronic renal failure, significant cardiovascular disease, established type 1 or type 2 diabetes mellitus, or active cancer within the past 5 years\n\n  * Smokers and alcoholics\n  * Pregnant females\n  * Presence of xerostomia\n  * Patients undergoing radiotherapy\n  * Having received professional periodontal treatment within the previous 6 months\n  * Having received antibiotic medication 3 months prior to study\n  * Periapical pathology or other oral inflammatory conditions\n  * Cognitive disability (interfering with ability to give sample)",true,"50 Years",{"count":49,"type":21},87,"According to 2017 World Workshop of Periodontology , the level of high sensitivity C reactive protein has been assumed to increase according to the grade of periodontitis, however, specific evidence regarding this is lacking at present. Hence, measuring high sensitivity C reactive protein in serum and oral rinse samples in systemically healthy individuals with periodontitis could be potentially useful in gaining insight on the systemic burden of periodontal disease.",[25],[53],"periodontits","NOT_YET_RECRUITING","2025-05-22",{"date":57,"type":30},"2025-05-30",{"date":59,"type":21},"2025-06-25",{"date":61,"type":21},"2026-08-25",{"name":63,"class":37},"Postgraduate Institute of Dental Sciences Rohtak"]